根据提交给美国证券交易委员会(SEC)的文件显示,Climb Bio Inc. 已登记由售股股东进行的普通股转售,涉及股份数量最高可达1160万股。此次提交意味着相关股东已获得在未来公开市场出售这部分股份的资格,但具体出售的时间、价格及数量将由股东自行决定。公司本身不会从此次售股中获得任何收益。
根据提交给美国证券交易委员会(SEC)的文件显示,Climb Bio Inc. 已登记由售股股东进行的普通股转售,涉及股份数量最高可达1160万股。此次提交意味着相关股东已获得在未来公开市场出售这部分股份的资格,但具体出售的时间、价格及数量将由股东自行决定。公司本身不会从此次售股中获得任何收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.